Business Wire

IDEMIA Acquires X Core Technologies’ Metal Payment Card Business and Launches Smart Metal Art Offer

17.10.2019 10:40:00 EEST | Business Wire | Press release

Share

At a time when demand for metal payment cards increases, IDEMIA, the global leader in Augmented Identity, broadens its existing offer with Smart Metal Art, a new metal payment card range fully suitable for contactless payments. Smart Metal Art comes from the acquisition of X Core’s metal payment card business and associated patents. Smart Metal Art is designed for the dual interface mass affluent market and is already certified by Visa, Mastercard and Amex.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191017005283/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

(Photo: Business Wire)

In a business environment with both online and offline offerings, metal payment cards have been massively adopted by users representing a booming market. A 2018 global consumer study indicated that more than 50% of consumers are willing to pay for a metal card, 70% of whom are under the age of 351. Fintech firms have nearly all adopted metal payment cards and major banks are also providing metal cards to their high net worth customers.

To satisfy this growing demand while still delivering the convenience customers expect, IDEMIA is investing to expand its leading offer of metal cards and launching Smart Metal Art suite of products. Smart Metal Art is the very first metal payment card fully suitable for contactless payments with no restrictions. It offers endless graphical possibilities thanks to its non-magnetic, decorated metal core, protected by layers that can be transparent or printed.

Smart Metal Art includes patented technology, developed by US firm X Core and recently acquired by IDEMIA. These patents allow for perfect dual interface performance, as well as decoration capabilities, which are then encapsulated within protective layers. Smart Metal Art will be manufactured by IDEMIA in our Exton (Pennsylvania, USA) facility.

At a time when banks need to differentiate strongly from one another, this game-changing technology gives them free reign over their card designs while allowing them to use unrivaled graphics such as etching or a brushed look combined with high-definition coloring techniques on their metal cards.

Thanks to this proprietary technology, IDEMIA will enable even more financial institutions to distribute its latest-generation dual-interface metal payment cards to premium customers, in volume around the world. IDEMIA’s end-to-end contactless metal card offer encompasses design, manufacture, personalization and product packaging.

Smart Metal Art has been certified by Visa, Mastercard and Amex, with no restriction on contactless performance, giving IDEMIA’s clients the opportunity of a very rapid go-to-market for their metal cards.

Amanda Gourbault, Executive Vice-President for Financial Institutions activities at IDEMIA said: “Payment cards are the latest marketing asset for banks for customer acquisition. Acquiring X Core is entirely consistent with IDEMIA’s strategy to offer cutting-edge technology to its customers without ever compromising on security or convenience. Our new offer, Smart Metal Art, delivers the best high-end cards combined with unmatched contactless payment features, which will be a game changer for end-users.

About IDEMIA

IDEMIA, the global leader in Augmented Identity, provides a trusted environment enabling citizens and consumers alike to perform their daily critical activities (such as pay, connect and travel), in the physical as well as digital space.
Securing our identity has become mission critical in the world we live in today. By standing for Augmented Identity, an identity that ensures privacy and trust and guarantees secure, authenticated and verifiable transactions, we reinvent the way we think, produce, use and protect one of our greatest assets – our identity – whether for individuals or for objects, whenever and wherever security matters. We provide Augmented Identity for international clients from Financial, Telecom, Identity, Public Security and IoT sectors.
With 13,000 employees around the world, IDEMIA serves clients in 180 countries.

For more information, visit www.idemia.com / Follow @IdemiaGroup on Twitter

About X Core Technologies LLC,

X Core Technologies LLC, is a US based enterprise providing Hot Lamination compatible Prelaminate Core Sheets incorporating advanced electronic functionality for the Payment, Security and Health Care sectors.

For more information, please visit www.X-Coretchnologies.com

----------

1 Phoenix Synergistic, 2016

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For business information, please contact:
Tim Wright, VP Metal Card and Advanced Card Bodies
Timothy.WRIGHT@idemia.com

Press
Hanna SEBBAH - idemia@havas.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye